Skip to main content
Premium Trial:

Request an Annual Quote

EMD Chemicals, Epitome Biosystems, Luminex, Taconic, Carestream Molecular Imaging, Kodak

Premium
EMD Chemicals, a subsidiary of Merck KGaA, this week launched WideScreen EpiTag ERK pathway assays, the first of its bead-based, multiplex assays using EpiTag technology licensed from Epitome Biosystems.
 
WideScreen EpiTag assays, performed on the xMAP technology-based line of instrument platforms from Luminex, use EpiTag technology, a highly targeted measurement platform for multiplex protein assays.
 
The first in a series of validated assay panels is available globally through the international sales and distribution network of the EMD/Merck group.
 
EMD and Epitome Biosystems have ongoing collaborations to develop EpiTag assays for additional targets in the ERK pathway and for membrane proteins.
 

 
Taconic this week introduced its HRN mouse, or the Hepatic Reductase Null mouse, for ADME/Tox studies.
 
Originally developed by Cancer Research UK and commercialized by CXR Biosciences, this conditional, targeted knockout of Por (cytochrome P450 reductase) in the liver results in the inactivation of all hepatic cytochrome P450 activity. As the cytochrome P450 system plays a major role in drug metabolism and disposition, this model is appropriate for efficacy, bioavailability, and ADME/Tox studies, the company said.
 
In addition, this model can also provide further information on whether the parent compound or its metabolite(s) are responsible for observed efficacy or toxicity, when compared to wild-type mice.
 
The lack of metabolism in the HRN also enables greater exposure to compounds without repeated dosing or the use of constant infusion pumps, even with high clearance compounds. The HRN mouse allows for the true dosing of parent compounds, which may not be otherwise possible, according to the manufacturer.
 
The model’s efficiency may help researchers reduce the number of experiments and animal use in lead selection, thus reducing costs, the company said.
 

 
Carestream Molecular Imaging has introduced new Kodak X-Sight large Stokes shift dye conjugates for fluorescent in vitro and in vivo imaging applications, the company announced this week. These new dye conjugates are available immediately for preclinical use.
 
According to the manufacturer, Kodak X-Sight large Stokes shift dye conjugates are appropriate for Western blotting applications. Other commercially available dyes that naturally have a large Stokes shift in the near infra-red range are not available, the company said.
 
Kodak X-Sight large Stokes shift dye conjugates are available conjugated to a variety of secondary antibodies in two distinct excitation and emission wavelengths in the near infrared range. To minimize cross reactivity, the secondary antibodies have been affinity purified and highly cross-adsorbed.
 
Although the Kodak X-Sight imaging agents have been optimized for Kodak in vivo imaging systems and Kodak image stations, they are also compatible with other commercially available digital imaging systems.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.